Literature DB >> 24692811

Effect of cartilage oligomeric matrix protein angiopoietin-1 on peripheral nerves in db/db diabetic mice.

Heung Yong Jin1, Ming Han Piao1, Ji Hyun Park1, Hong Sun Baek1, Sik Lee2, Won Kim2, Sung Kwang Park2, Chong Hwa Kim3, Gou Young Koh4, Tae Sun Park1.   

Abstract

BACKGROUND: Vascular and inflammatory processes have been reported to be factors in the pathogenesis of diabetic neuropathy. Angiopoietin-1 (Ang1) plays essential roles in regulating vascular growth, development, maturation, permeability, and inflammation.
OBJECTIVE: The aim of this study was to investigate the effect of cartilage oligomeric matrix protein (COMP)-Ang1, which is a soluble, stable, potent Ang1 variant, on peripheral nerves in db/db diabetic mice.
METHODS: The db/db diabetic mice were randomized into 2 groups based on their weight and glucose level and treated with recombinant adenovirus (Ade), expressing either COMP-Ang1 or the β-galactosidase gene (LacZ) (control), for 8 weeks. Immunohistochemistry was performed using a polyclonal antibody of antiprotein gene product and a secondary antibody. Intraepidermal nerve fiber density (IENFD) was quantified as nerve fiber abundance per unit length of epidermis (IENF/mm). In addition, the total capillary length (TCL) per unit length of epidermis was summed (mm/mm(2)). All slides were coded and the capillary length and the number of nerve fibers were calculated by a blinded observer.
RESULTS: Ten diabetic db/db mice (mean [SD] weight, 38.7 [1.95] g) were randomized to receive Ade-COMP-Ang1 or Ade-LacZ. IENFD was significantly greater in the Ade-COMP-Ang1 group compared with the Ade-LacZ group (mean [SD] 8.95 [3.30] vs 3.57 [0.73]/mm; P < 0.05). TCL was also significantly greater in the Ade-COMP-Ang1 group (2.79 [0.99] vs 2.04 [0.58] mm/mm(2); P < 0.05). Compared with baseline, fasting blood glucose concentration after 8 weeks of treatment decreased significantly more in the Ade-COMP-Ang1 group than in the Ade-LacZ group (489 [45] to 361 [81] vs 495 [48] to 521 [70] mg/dL; P < 0.05).
CONCLUSIONS: These results suggest that Ade-COMP-Ang1 might have had proliferative effects on peripheral nerve and cutaneous capillaries in this small animal study. Further investigation of the metabolic effect, target site, and related mediator of COMP-Ang1 is needed.

Entities:  

Keywords:  COMP-angiopoietin-1; db/db diabetic mice; peripheral neuropathy

Year:  2008        PMID: 24692811      PMCID: PMC3969925          DOI: 10.1016/j.curtheres.2008.08.002

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  30 in total

1.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.

Authors:  T Nishikawa; D Edelstein; X L Du; S Yamagishi; T Matsumura; Y Kaneda; M A Yorek; D Beebe; P J Oates; H P Hammes; I Giardino; M Brownlee
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

Review 2.  Aldose reductase inhibitors and diabetic complications.

Authors:  D R Tomlinson; G B Willars; A L Carrington
Journal:  Pharmacol Ther       Date:  1992       Impact factor: 12.310

3.  Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study.

Authors:  S Tesfaye; L K Stevens; J M Stephenson; J H Fuller; M Plater; C Ionescu-Tirgoviste; A Nuber; G Pozza; J D Ward
Journal:  Diabetologia       Date:  1996-11       Impact factor: 10.122

Review 4.  Diabetic neuropathies: a statement by the American Diabetes Association.

Authors:  Andrew J M Boulton; Arthur I Vinik; Joseph C Arezzo; Vera Bril; Eva L Feldman; Roy Freeman; Rayaz A Malik; Raelene E Maser; Jay M Sosenko; Dan Ziegler
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

5.  Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats.

Authors:  Mika Nakae; Hideki Kamiya; Keiko Naruse; Naoichi Horio; Yasuki Ito; Ryuichi Mizubayashi; Yoji Hamada; Eitaro Nakashima; Noboru Akiyama; Yasuko Kobayashi; Atsuko Watarai; Nachi Kimura; Masayuki Horiguchi; Yasuhiko Tabata; Yutaka Oiso; Jiro Nakamura
Journal:  Diabetes       Date:  2006-05       Impact factor: 9.461

6.  Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats.

Authors:  Naoki Kato; Koichi Nemoto; Kuniaki Nakanishi; Ryuichi Morishita; Yasufumi Kaneda; Maki Uenoyama; Tomosumi Ikeda; Kyosuke Fujikawa
Journal:  Diabetes       Date:  2005-03       Impact factor: 9.461

7.  Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes.

Authors:  Sik Lee; Won Kim; Sang-Ok Moon; Mi Jeong Sung; Duk Hoon Kim; Kyung Pyo Kang; Kyu Yoon Jang; Sang Yong Lee; Byung Hyun Park; Gou Young Koh; Sung Kwang Park
Journal:  Nephrol Dial Transplant       Date:  2006-11-03       Impact factor: 5.992

8.  Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy.

Authors:  P J Dyck; B R Zimmerman; T H Vilen; S R Minnerath; J L Karnes; J K Yao; J F Poduslo
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

9.  Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse.

Authors:  James R Goss; William F Goins; David Lacomis; Marina Mata; Joseph C Glorioso; David J Fink
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

10.  COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity.

Authors:  Chung-Hyun Cho; Richard A Kammerer; Hyuek Jong Lee; Michel O Steinmetz; Young Shin Ryu; Sung Ho Lee; Kunio Yasunaga; Kyung-Tae Kim; Injune Kim; Han-Ho Choi; Won Kim; Sung Hyun Kim; Sung Kwang Park; Gyun Min Lee; Gou Young Koh
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-01       Impact factor: 11.205

View more
  1 in total

1.  Angiopoietin-1/Tie2 signaling pathway contributes to the therapeutic effect of thymosin β4 on diabetic peripheral neuropathy.

Authors:  Lei Wang; Michael Chopp; Alexandra Szalad; XueRong Lu; Mei Lu; Talan Zhang; Zheng Gang Zhang
Journal:  Neurosci Res       Date:  2018-10-13       Impact factor: 3.304

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.